David Johnson, M.D.

David H. Johnson, M.D. is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center, and a member of its Division of Hematology-Oncology. A specialist in lung cancer, he holds the R. Ellwood Jones, M.D. Distinguished Professorship in Clinical Education.

Dr. Johnson received his medical degree from the Medical College of Georgia and completed internal medicine residency training at Mary Imogene Bassett Hospital in Cooperstown, New York. He then completed advanced training through a fellowship in medical oncology at Vanderbilt University in Nashville.

Certified by the American Board of Internal Medicine in internal medicine and medical oncology, he served on the faculties of the Medical College of Georgia and Vanderbilt University School of Medicine before joining the UT Southwestern faculty in 2010 as the Chair of Internal Medicine.

Dr. Johnson’s research interests involve understanding the biology of lung cancer and improving treatment of this and other solid tumors. Over the course of his career he played a major role in the development of several therapeutic agents including paclitaxel (Taxol), bevacizumab (Avastin) and erlotinib (Tarceva) all of which are now FDA-approved for the treatment of lung cancer. He also played a role in the clinical development of G-CSF culminating in its FDA approval.

His investigations have resulted in more than 450 publications in peer-reviewed journals and more than 50 book chapters and monographs. He served as editor for the textbooks Lung Cancer, Principles & Practice and the Textbook of Uncommon Cancer.

He is a past Chair of the American Board of Internal Medicine (ABIM) Board of Directors, and of ABIM Medical Oncology Subspecialty Board. He has served as President of the American Society of Clinical Oncology (ASCO), where he helped advance the organization’s quality of care activity known as the Quality Oncology Practice Initiative (QOPI) and was instrumental in establishing ASCO’s Cancer Survivorship Program.

Dr. Johnson also served on the Food and Drug Administration’s Oncology Drug Advisory Committee, as chairman of the Thoracic Committee of the Eastern Cooperative Oncology Group and on the Board of Directors of the National Comprehensive Cancer Network, the International Association for the Study of Lung Cancer and the LiveSTRONG Foundation.

Medical School

Medical College of Georgia at Augusta University (1976)

Internship

Mary Imogene Bassett Hospital (1976), Internal Medicine

Residency

University of South Alabama Medical Center (1979), Internal Medicine

Fellowship

Vanderbilt University Medical Center (1983), Hematology Oncology

• Developmental therapeutics
• Lung cancer therapeutics

Featured Publications

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.

Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretic L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, Buettner R, Ansén S, Perner S, Brockmann M, Bos M, Wolf J, Gardizi M, Wright GM, Solomon B, Russell PA, Rogers TM, Suehara Y, Red-Brewer M, Tieu R, de Stanchina E, Wang Q, Zhao Z, Johnson DH, Horn L, Wong KK, Thomas RK, Ladanyi M, Pao W Nat. Med. 2014 Aug

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD The Lancet 2009 374 379-86

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH N Engl J Med 2006 355 2542-50

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

Winton T, Livingston R, Johnson DH, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao M-S, Gandara D, Kesler K, Demmy T, Shepherd F N Engl J Med 2005 352 2589-97

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH N Engl J Med 2002 346 92-8

A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group

Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, Perry MC, Livingston RB, Johnson DH N Engl J Med 2000 343 1217-22

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH N Engl J Med 1999 340 265-71

Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data.

Lancet 2014 May 383 9928 1561-71

Clinical course of advanced non-small cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH J Clin Oncol 2010 28 949-54

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data.

NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, Le Pechoux C, Parmar MK, Pignon JP, Souhami RL, Stephens RJ, Stewart LA, Tierney JF, Tribodet H, van Meerbeeck J. The Lancet 2010 375 1267-77

 Featured Books

Lung Cancer, Principles & Practice.

Harvey I. Pass, David P. Carbone, David H. Johnson, John D. Minna, G. Scagliotti, Andrew T. Turrisi, eds. (Ed.) (2010). Philadelphia, Lippincott Williams & Wilkins

Textbook of Uncommon Cancer - 4th ed

D. Raghavan, C.D. Blanke, D.H. Johnson, P.L. Moots, G.H. Reaman, P.G. Rose, M.K. Sekeres; eds (Ed.) (2012). Hoboken, NJ, Wiley-Blackwell

• Giants in Cancer Care Award
  (2019)
• ASCO Distinguished Achievement Award
  (2016)
• College of Arts & Sciences Hall of Fame, University of Kentucky
  (2015)
• Master, American College of Physicians
  (2015)
• Chairman, American Board of Internal Medicine Board of Directors
  (2013-2015)
• Established Investigator Award, CPRIT
  (2010)
• Association of American Physicians
  (2009)
• Distinguished Southern Oncologist Award, Southern Association of Oncology
  (2006)
• President, American Society of Clinical Oncology
  (2004-2005)
• Alpha Omega Alpha
  (1975)

• American Association for Cancer Research
• American College of Physicians
• American Society of Clinical Oncology
• Association of American Physicians
• International Association for the Study of Lung Cancer